Diagnostics and biomarker development: Priming the pipeline

Nature Reviews Drug Discovery

Volumn 5, Issue 6, 2006, Pages 463-469

  Phillips, Kathryn A ^a   Van Bebber, Stephanie ^a   Issa, Amalia M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; NEW DRUG;

ARTICLE; BASIC RESEARCH; CLINICAL PRACTICE; DEVICE; DIAGNOSTIC TEST; DRUG DESIGN; INVESTMENT; LABORATORY TEST; MEDICARE; PRIORITY JOURNAL; REIMBURSEMENT; APPARATUS, EQUIPMENT AND SUPPLIES; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERVIEW; ORGANIZATION; REVIEW; UNITED STATES;

BIOLOGICAL MARKERS; CONGRESSES; DRUG DESIGN; EQUIPMENT AND SUPPLIES; HUMANS; INTERVIEWS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33745954240     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2033     Document Type: Article

References (48)

1. US Department of Health and Human Services, Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products [online], (2004).
2. US Department of Health and Human Services, Food and Drug Administration. Critical Path Opportunities Report [online], (2006).
3. AdvaMed. AdvaMed's submitted comments on FDA's Critical Path Intitiative [online], (2004).
4. Tsongalis, G. J. A reality check for molecular diagnostics in clinical practice. Pharmacogenomics 4, 667-668 (2003).
5. Woodcock, J. The Critical Path: One Year Later. Presentation at the FDA/ DIA/BIO Meeting: Use of Medical Imaging as a Drug Development Tool [online], (2005).
6. AdvaMed. The medical technology industry at a glance [online], (2004).
7. US Food and Drug Administration & Gutman, S. OIVD Requests a Meeting with Roche Diagnostics Regarding the AmpliChip CYP450 Microarray [online], (2005).
8. US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Center for Devices and Radiological Health: Promoting and Protecting the Public Health [online], (2004).
9. Hall, S. & Casper, A. Presentation at FDA/industry IVD Roundtable 10 November (2004).
10. The Lewin Group Inc. The Value of Diagnostics: Innovation, Adoption and Diffusion Into Health Care [online], (2005).
11. Melzer, D., Zimmern, R. L. & Ling, T. Regulatory options for pharmacogenetics. Pharmacogenomics 4, 527-530 (2003).
12. US Department of Health and Human Services. Secretary's Advisory Committee on Genetics, Health, and Society - Third Meeting 1-2 March 2004 [online], (2004).
13. Institute of Medicine. Medicare Laboratory Payment Policy Now And In The Future [online], (2000).
14. Department of Health and Human Services, Secretarys Advisory Committee on Genetics Health and Society. Coverage and Reimbursement of Genetic Tests and Services: Report of the Secretary's Advisory Committee on Genetics, Health, and Society, Public Comment Draft [online], (2005).
15. Kessler, L., Ramsey, S. D., Tunis, S. & Sullivan, S. D. Clinical use of medical devices in the 'Bermuda Triangle'. Health Affairs 23, 200-207 (2004).
16. Hoag, H. Testing new ground. Nature 429, 682-683 (2004).
17. Ito, R. K. & Demers, L. M. Pharmacogenomics and pharmacogenetics: Future role of molecular diagnostics in the clinical diagnostic laboratory. Clin. Chem. 50, 1526-1527 (2004).
18. Sannes, L. J. Molecular Diagnostics: Technological Advances Fueling Market Expansion CHI Report #33 (Cambridge Healthtech Institute; www.chireports.com; 2003).
19. Danzon, P. M., Nicholson, S. & Pereira, N. S. Productivity in pharmaceutical-biotechnology R&D: The role of experience and alliances. J. Health Econ. 24, 317-339 (2005).
20. Womack, C. In 'Critical Path' Update, Novartis Official Said Industry Should Share Biomarker Data. The Pharmacogenomics Reporter 12/9 (2004).
21. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CIDER). Guidance for Industry: Pharmacogenomic Data Submissions [online], (2005).
22. Frueh, F. W. HHS Efforts and Future Directions in Pharmacogenomics - An Update on FDA Guidances Related to Pharmacogenomics. Presentation June 16, 2005 to the Secretarys Advisory Committe on Genetics, Health, and Society [online], (2005).
23. Department of Health and Human Services, Food and Drug Administration. Drug-Diagnostic Co-Development Concept Paper [online], (2005).
24. Wechsler, J. Drug development linked more closely to diagnostics. Pharmaceutical Technol. October (2004).
25. Brazma, A. et al. Minimum information about microarray experiment (MIAME)- towards standards for microarray data. Nature Genet. 29, 365-371 (2001).
26. Biotechnology Industry Organization. BIO Comments to Docket No. 2004N-0181 [online], (2004).
27. Swain, E. Forging new regulatory pathways at FDA [online], (2004).
28. Wadman, M. Drug safety special: The safety catch. Nature 434, 554-556 (2005).
29. Lindpaintner, K. Pharmacogenetics and the future of medical practice. J. Mol. Med. 81, 141-153 (2003).
30. Rothstein, M. A. Genetic exceptionalism and legislative pragmatism. Hastings Cent. Rep. 35, 27-33 (2005).
31. Lai, E. Pharmacogenetics The GSK Perspective. Presentation June 16, 2005 [online], (2005).
32. Zineh, I. et al. Availability of pharmacogenomics-based prescribing information in currently approved drugs. Pharmacogenomics J. 4, 354-358 (2004).
33. Buchanan, A. et al. Pharmacogenetics: Ethical issues and policy options. Kennedy Inst. Ethics J. 12, 1-15 (2002).
34. Robertson, J. A., Brody, B., Buchanan, A., Kahn, J. & McPherson, E. Pharmacogenetic challenges for the health care system. Health Affairs 21, 155-167 (2002).
35. Secretary's Advisory Committee on Genetics Health and Society. Second Meeting, October 22-23 2003.
36. Manasco, P. K. & Arledge, T. E. in Pharmacogenomics: Social, Ethical, and Clinical Dimensions (Rothstein, M. A. ed.) 83-97 (John Wiley & Sons, New Jersey, 2003).
37. Gutman, S. The role of Food and Drug Administration Regulation of in vitro diagnostic devices - applications in genetics testine. Clin. Chem. 45, 746-749 (1999).
38. Berry, C. Coverage and Reimbursement of Genetic Tests and Services: Review of Public Comments and Finalization of SACGHS Report. Presentation June 16, 2005 [online], (2005).
39. Phillips, K. A., Veenstra, D., Van Bebber, S. L. & Sakowski, J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 4, 231-239 (2003).
40. Phillips, K. A. & Van Bebber, S. L. Measuring the value of pharmacogenomics. Nature Rev. Drug Discov. 4, 500-509 (2005).
41. Gurwitz, D., Weizman, A. & Rehavi, M. Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol. Sci. 24, 122-125 (2003).
42. Feigal, D. W. & Gutman, S. in Pharmacogenomics: Social, Ethical, and Clinical Dimensions (Rothstein, M. A. ed.) 99-108 (John Wiley & Sons, New Jersey, 2003).
43. US Food and Drug Administration. Guidance for Industry and FDA Staff: Class II Special Controls Guidance Document: Drug Metabolizing Enzyme GenotypingSystem [online], (2005).
44. US Food and Drug Administration. Analyte Specific Reagents: Small Entity Compliance Guidance - Guidance for Industry [online], (2003).
45. Gold, M., Siegel, J., Russell, L. & Weinstein, M. Cost-Effectiveness in Health and Medicine (Oxford Univ. Press, New York, 1996).
46. Phillips, K. A. & Van Bebber, S. L. Cost-effectiveness of pharmacogenomic interventions: A systematic review of the literature. Pharmacogenomics 5, 1139-1149 (2004)
47. Issa, A. M. The regulation of pharmacogenomics-based drugs and policy making. Curr. Top. Med. 4, 1455-1460 (2004).
48. Phillips, K. A., Ackerman, M. J., Sakowski, J. & Berul, C. I. Cost-effectiveness analysis of genetic testing for familial long OT syndrome in symptomatic index cases. Heart Rhythm. 2, 1294-1300 (2005).